Stay updated on REOLYSIN in KRAS Mutant CRC Clinical Trial

Sign up to get notified when there's something new on the REOLYSIN in KRAS Mutant CRC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the REOLYSIN in KRAS Mutant CRC Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    7 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the maximum tolerated dose of REOLYSIN® combined with FOLFIRI and bevacizumab in a Phase 1 dose-escalation study for patients with KRAS mutant metastatic colorectal cancer.
    Difference
    0.1%
    Check dated 2024-06-06T14:37:09.000Z thumbnail image
  7. Check
    22 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to provide detailed eligibility criteria for study participants, including specific health conditions and prior treatments required for inclusion. Previously, this section only indicated that no information was provided.
    Difference
    34%
    Check dated 2024-05-22T21:26:10.000Z thumbnail image
  8. Check
    44 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:53:35.000Z thumbnail image

Stay in the know with updates to REOLYSIN in KRAS Mutant CRC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the REOLYSIN in KRAS Mutant CRC Clinical Trial page.